Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Total Non-Current Liabilities (2021 - 2023)

Historic Total Non-Current Liabilities for Inmune Bio (INMB) over the last 3 years, with Q3 2023 value amounting to $17.2 million.

  • Inmune Bio's Total Non-Current Liabilities changed N/A to $17.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $17.2 million, marking a year-over-year change of. This contributed to the annual value of $21.1 million for FY2022, which is 720.59% up from last year.
  • According to the latest figures from Q3 2023, Inmune Bio's Total Non-Current Liabilities is $17.2 million.
  • In the past 5 years, Inmune Bio's Total Non-Current Liabilities registered a high of $21.1 million during Q4 2022, and its lowest value of $17.2 million during Q3 2023.
  • Its 3-year average for Total Non-Current Liabilities is $18.9 million, with a median of $18.9 million in 2021.
  • Examining YoY changes over the last 5 years, Inmune Bio's Total Non-Current Liabilities showed a top increase of 720.59% in 2022 and a maximum decrease of 720.59% in 2022.
  • Over the past 3 years, Inmune Bio's Total Non-Current Liabilities (Quarter) stood at $19.7 million in 2021, then increased by 7.21% to $21.1 million in 2022, then decreased by 18.82% to $17.2 million in 2023.
  • Its last three reported values are $17.2 million in Q3 2023, $21.1 million for Q4 2022, and $18.7 million during Q1 2022.